There is a newer version of the record available.

Published April 2020 | Version v1
Journal article

Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis

  • 1. Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute. Department of Radiotherapy (China)
  • 2. Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute. Department of Surgery (China)
  • 3. Liaoning Cancer Hospital and Institute. Physical Laboratory in Charge, Department of Radiotherapy Department (China)
  • 4. China Medical University (China)
  • 5. Chengdu Medical College (China)
  • 6. Liaoning Cancer Hospital and Institute. Department of Cerebral Surgery (China)
  • 7. Liaoning Cancer Hospital and Institute. Department of Information Management (China)
  • 8. China Medical University. Department of Epidemiology, School of Public Health (China)
  • 9. The First Hospital of China Medical University. Department of Radiotherapy (China)

Description

Purpose

: In this retrospective study, we evaluated the treatment patterns and survival after positron emission tomography-computed tomography (PET/CT)-guided local consolidation therapy (LCT) for oligometastatic non-small cell lung cancer (NSCLC).

Methods

: We reviewed the medical records of Chinese patients with oligometastatic stage IV non-small cell lung cancer (≤ 5 metastases) who had undergone PET/CT and were eligible for systemic therapy at two centers between May 2005 and August 2019. Propensity score matching (1:1) was used to reduce selection bias and imbalanced distribution of confounding factors.

Results

: We identified 84 eligible patients and used propensity scores to create well-matched groups of 35 patients who did or did not undergo LCT. Among all patients, the 1-year overall survival (OS) rate was 47.6% and the 2-year OS rate was 22.6%. Relative to the group that did not receive LCT, the LCT group had a significantly higher OS rate (13 months vs. 7 months, p = 0.002). The two groups had similar incidences and classifications of LCT-related side effects. In multivariable analysis, LCT was found to be strongly associated with a favorable OS (hazard ratio: 0.508, 95% confidence interval: 0.311–0.828, p = 0.001).

Conclusion

: We concluded that LCT was significantly associated with improved clinical outcomes among the Chinese patients with oligometastatic NSCLC who were eligible for systemic treatment and could undergo PET/CT evaluation.

Additional details

Identifiers

Publishing Information

Journal Title
Journal of Cancer Research and Clinical Oncology
Journal Volume
146
Journal Issue
4
Journal Page Range
p. 1021-1031
ISSN
0171-5216
CODEN
JCROD7

Optional Information

Copyright
Copyright (c) 2020 © The Author(s) 2020